AstraZeneca’s low-carbon inhaler virtually eliminates climate impacts

illuminem summarises for you the essential news of the day. Read the full piece on Trellis or enjoy below:

🗞️ Driving the news: AstraZeneca has received regulatory approval in the U.K. for a low-carbon version of its Trixeo Aerosphere inhaler, replacing the traditional high-emission propellant with HFO-1234ze(E), a next-generation compound with 99.9% lower global warming potential
• The move marks a major breakthrough in healthcare decarbonisation, offering a climate-friendly alternative without compromising clinical effectiveness

🔭 The context: Pressurised metered-dose inhalers (pMDIs) are the most-used respiratory treatments globally, but their hydrofluorocarbon (HFC) propellants are significant greenhouse gas contributors
• Inhalers account for 3% of the U.K. National Health Service’s carbon footprint and about 0.04% of global emissions
• AstraZeneca’s approval sets a precedent as governments, including in the EU, China, and the U.S., evaluate similar transitions

🌍 Why it matters for the planet: This regulatory milestone demonstrates that environmental responsibility and clinical efficacy can coexist
• The widespread adoption of low-GWP inhalers has the potential to substantially reduce healthcare’s carbon footprint, an industry responsible for 4.5% of global emissions
• It also reinforces the importance of decarbonising medical products without limiting patient access or outcomes

⏭️ What's next: The low-carbon Trixeo will launch in the U.K. in late 2025, with regulatory reviews underway in the EU, China, and the U.S. AstraZeneca plans to transition its entire pressurised inhaler portfolio by 2030, backed by a $500 million investment
• As competition heats up, including from GSK’s upcoming Ventolin reformulation, the low-carbon inhaler segment may become a new standard in respiratory care

💬 One quote: “Clinicians and their patients shouldn’t feel that they have to choose between the most appropriate treatment and the planet,” — Omar Usmani, Professor of Respiratory Medicine at Imperial College London

📈 One stat: Pharmaceutical companies emit an average of 48 metric tons of CO₂e per $1 million in revenue — 55% more per dollar than the automotive sector

Click for more news covering the latest on sustainable wellbeing and corporate sustainability